
-
CytomX Therapeutics NasdaqGS:CTMX CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Location: 151 Oyster Point Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.cytomx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
131.4M
Cash
79.89M
Avg Qtr Burn
-20.31M
Short % of Float
29.07%
Insider Ownership
0.83%
Institutional Own.
51.06%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CX-2051 Details Cancer, Metastatic colorectal cancer | Phase 1a Data readout | |
CX-801 + KEYTRUDA Details Cancer, Solid tumor/s, Melanoma | Phase 1a Data readout | |
CX-904 (EGFRxCD3) Details Cancer, Solid tumor/s | Failed Discontinued | |
Pacmilimab (CX-072) + CX-2009 (PD-L1 Targeting Probody Immunotherapy + CD166 PDC) Details Cancer, Triple-negative breast cancer | Failed Discontinued | |
BMS-986249 (CTLA-4-directed Probody therapeutic) Details Cancer, Melanoma | Failed Discontinued | |
Praluzatamab ravtansine (CX-2009) (anti-CD166) Details Cancer, HER2-expressing cancers, Breast cancer | Failed Discontinued | |
CX-2029 (PDC directed against CD71) Details Non-small cell lung carcinoma, Head and neck squamous cell carcinoma, Cancer, Solid tumor/s | Failed Discontinued | |
BMS-986288 (Anti-CTLA-4 non-fucosylated Probody) Details Solid tumor/s, Colorectal cancer | Failed Discontinued |